| Detailed information |
|---|
| CancerLivER ID | 2509 |
| Biomarker | CCL20, S100P, PEG10, SGCE, XAGE-1, COL4A1, ZNF83, and TM4SF1 |
| Biomarker Name/Symbol (given in Publication) | CCL20, S100P, PEG10, SGCE, XAGE-1, COL4A1, ZNF83, and TM4SF1 |
| Biomolecule | RNAs |
| Subject | Human |
| Degree of Validity | Significantly Upregulated in HCC than non-tumor and validated on independent dataset |
| Experimental Condition | HCC v/s non-tumor |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Upregulated in HCC than non-tumor (with > 3 fold change) |
| Level of significance | p < 0.05 |
| Source | Cell line, Tissue |
| PMID | 19171046 |
| Type of Biomarker | Diagnostic |
| Pathway | Interleukin-10 signaling and TNF signaling pathway, Validated target for C-MYC transcriptional activation. |
| Cohort | Training dataset: HCC cell line HepG2 , Normal liver tissue was obtained from a patient, Validation datasets: 20 pairs of HCC and adjacent nontumorous liver tissues; |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | HCC v/s non-tumor |
| Year of Publication | 2009 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |